OpenLB
Open Library of Bioscience
Advanced Search
Bioengineered
02, 2022;13 (2): 2296-2307.

Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia.

Yabo Liu, Huibo Li, Yanqiu Zhao, Dandan Li, Qian Zhang, Jinyue Fu, Shengjin Fan
Author Information
  1. Yabo Liu: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  2. Huibo Li: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  3. Yanqiu Zhao: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  4. Dandan Li: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  5. Qian Zhang: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  6. Jinyue Fu: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  7. Shengjin Fan: Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. ORCID
PMID: 35034552 DOI: 10.1080/21655979.2021.2024389

Abstract

Long non-coding RNAs (LncRNAs) exert important regulatory roles in chronic myeloid leukemia (CML). In this study, we aimed to investigate the potential role and molecular mechanism of lncRNA ADORA2A antisense RNA 1 (ADORA2A-AS1) in CML. We found that the expression of ADORA2A-AS1 was upregulated in CML. Further, knockdown of ADORA2A-AS1 inhibited the proliferation, induced apoptosis, arrested cell cycle, and enhanced imatinib sensitivity in CML cells. Besides, ADORA2A-AS1 promoted the expression of transforming growth factor-beta receptor 1 (TGFBR1) and ATP binding cassette subfamily C member 2 (ABCC2) via sponging miR-665, thereby exerting a tumor-promoting activity. Collectively, our results confirmed the oncogenic effect of ADORA2A-AS1 in CML, indicating that ADORA2A-AS1 is a promosing therapeutic target for CML.

Keywords

ADORA2A-AS1 Chronic myeloid leukemia miR-665

References

  1. Brief Funct Genomics. 2016 May;15(3):239-48 [PMID: 26647283]
  2. Cell Death Dis. 2018 Jun 13;9(6):706 [PMID: 29899418]
  3. Mol Ther. 2021 May 5;29(5):1838-1852 [PMID: 33545359]
  4. Cancer Sci. 2019 Mar;110(3):913-925 [PMID: 30582654]
  5. Curr Cancer Drug Targets. 2013 Sep;13(7):779-90 [PMID: 23906053]
  6. Cancer Manag Res. 2018 Nov 05;10:5349-5362 [PMID: 30464631]
  7. FEBS Lett. 2007 Apr 3;581(7):1329-34 [PMID: 17349636]
  8. Leuk Lymphoma. 2017 Dec;58(12):2799-2810 [PMID: 28482729]
  9. Oncogene. 2015 Apr 2;34(14):1768-79 [PMID: 24837367]
  10. Protein Cell. 2015 Jun;6(6):403-12 [PMID: 25749979]
  11. Anticancer Res. 2020 May;40(5):2457-2465 [PMID: 32366389]
  12. Mol Cell Biochem. 2021 Jan;476(1):109-123 [PMID: 32975695]
  13. Cell Death Dis. 2019 Jun 17;10(7):479 [PMID: 31209222]
  14. FEBS Lett. 2019 Aug;593(15):1993-2007 [PMID: 31180580]
  15. Int J Mol Sci. 2019 Nov 08;20(22): [PMID: 31717266]
  16. Exp Ther Med. 2020 Feb;19(2):1112-1120 [PMID: 32010277]
  17. Bioengineered. 2021 Dec;12(1):8217-8232 [PMID: 34596006]
  18. Cell Biochem Funct. 2020 Jun;38(4):409-418 [PMID: 31923339]
  19. Oncol Rep. 2021 Feb;45(2):557-568 [PMID: 33416164]
  20. Oncol Rev. 2020 Jul 06;14(2):448 [PMID: 32676170]
  21. J Exp Clin Cancer Res. 2020 Apr 26;39(1):71 [PMID: 32336285]
  22. J Cancer. 2019 Jun 10;10(17):3893-3898 [PMID: 31417632]
  23. Bioengineered. 2021 Dec;12(1):162-171 [PMID: 33356805]
  24. Mol Cancer. 2018 Aug 28;17(1):130 [PMID: 30153828]
  25. Curr Drug Targets. 2021;22(1):38-51 [PMID: 33050861]
  26. Am J Cancer Res. 2017 Aug 01;7(8):1704-1713 [PMID: 28861326]
  27. Bioengineered. 2021 Dec;12(2):9239-9250 [PMID: 34806925]
  28. Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7 [PMID: 24297251]
  29. Bioengineered. 2021 Dec;12(1):8006-8019 [PMID: 34595994]
  30. Crit Rev Oncol Hematol. 2016 Jan;97:263-74 [PMID: 26412717]
  31. Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2103-2111 [PMID: 30915755]
  32. Nat Hum Behav. 2020 Mar;4(3):308-316 [PMID: 31959922]
  33. Bioengineered. 2021 Dec;12(1):5476-5490 [PMID: 34511033]
  34. Mol Ther Nucleic Acids. 2020 Mar 6;19:1368-1378 [PMID: 32160707]
  35. Hum Cell. 2020 Oct;33(4):1273-1280 [PMID: 32779154]

MeSH Term

Adult
Cell Proliferation
Drug Resistance, Neoplasm
Female
Gene Knockdown Techniques
HEK293 Cells
Humans
Imatinib Mesylate
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
RNA, Antisense
RNA, Neoplasm

Chemicals

RNA, Antisense
RNA, Neoplasm
Imatinib Mesylate
Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Word Cloud

Created with Highcharts 10.0.0ADORA2A-AS1CMLmyeloidleukemia1chronicADORA2AantisenseRNAexpressionproliferationcellimatinibsensitivitymiR-665Longnon-codingRNAsLncRNAsexertimportantregulatoryrolesstudyaimedinvestigatepotentialrolemolecularmechanismlncRNAfoundupregulatedknockdowninhibitedinducedapoptosisarrestedcycleenhancedcellsBesidespromotedtransforminggrowthfactor-betareceptorTGFBR1ATPbindingcassettesubfamilyCmember2ABCC2viaspongingtherebyexertingtumor-promotingactivityCollectivelyresultsconfirmedoncogeniceffectindicatingpromosingtherapeutictargetKnockdowninhibitsenhancesChronic

Similar Articles

Cited By